CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 438 resultados LastUpdate Última actualización 13/08/2022 [12:59:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Página1 de 18 nextPage   por página


CATALYTIC AMPLIFICATION BY TRANSITION-STATE MOLECULAR SWITCHES FOR DIRECT AND SENSITIVE DETECTION OF SARS-COV-2

NºPublicación: WO2022169412A1 11/08/2022

Solicitante:

NAT UNIV SINGAPORE [SG]

Resumen de: WO2022169412A1

The present invention relates to the detection of target nucleic acids using enzyme-assisted nanotechnology. More specifically, the present invention provides a molecular nanotechnology in the form of a transition-state DNA-enzyme molecular switch and methods of use that enables direct and sensitive detection of viral RNA targets in native clinical samples. In one embodiment, the detection comprising steps of providing a composition comprising at least one DNA polymerase enzyme, at least one enhancer, and at least one DNA polymerase inhibitor, wherein the DNA polymerase inhibitor is recognized and bound by the DNA polymerase enzyme via its conserved region, and is complementary to a portion of the enhance via its variable region. In another embodiment, the detection method comprising steps of providing a signalling nanostructure and detecting signal development, wherein a change in the intensity of signal. In an alternative embodiment, the target nucleic acid is a SARS-CoV-2 polynucleotide.

traducir

Compositions for managing chronic obstructive pulmonary disease

NºPublicación: AU2021207536A1 11/08/2022

Solicitante:

SAMI SABINSA GROUP LTD

WO_2021146648_A1

Resumen de: AU2021207536A1

The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% wVw curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung lunction during prognosis.

traducir

SYSTEMS AND METHODS FOR SCREENING SUBJECTS BASED ON PUPILLARY RESPONSE TO OLFACTORY STIMULATION

NºPublicación: WO2022169485A1 11/08/2022

Solicitante:

GREAT PLAIN TECH LLC [US]

US_2022240836_A1

Resumen de: WO2022169485A1

A system and method for screening a subject for a pupillary response to an olfactory stimulus as an indication for COVID-19. The method can include providing the olfactory stimulus to the subject via a scent dispenser, measuring a pupillary response of the subject to the olfactory stimulus via a detector, and comparing the measured pupillary response to a reference. The reference could include a default value or a characterized pupillary response for the subject or a population of individuals to the olfactory stimulus. The method can further include determining whether the subject demonstrates a diminished or an absent response to the olfactory stimulus according to whether the measured pupillary response differs from the reference by a threshold and providing an alert accordingly. The alert can include an intervention associated with COVID-19, such a recommendation to seek medical evaluation or take a COVID-19 diagnostic test.

traducir

PROCESS FOR PREPARING NANOFORMULATION FOR DELIVERY OF BERBAMINE

NºPublicación: WO2022168123A1 11/08/2022

Solicitante:

PANJAB UNIV CHANDIGARH [IN]

Resumen de: WO2022168123A1

The present invention relates to a simple and convenient process for preparing solid lipid sustained release nanoparticles for berbamine delivery. The process involves preparation of nanoparticles by maintaining the pH of the aqueous or lipid phase so that high drug loading of 12-50 % w/w with respect to the lipid matrix and high entrapment efficiency of more than 90% for berbamine in the solid lipid nanoparticles is achieved. The nanoformulation obtained by the process of the present invention has increased efficacy and exhibited any therapeutic property identical to free berbamine such as antiviral-cum-antibacterial agent for the treatment of microbial infections especially resistant Acinetobacter infections in treating diabetes and more specifically diabetes associated complications. Use may be extended to other diseases like COVID 19.

traducir

UNIVERSAL ANTI-CORONAVIRUS CONSERVATIVE EPITOPE IGY AND BROAD-SPECTRUM ANTI-NOVEL CORONAVIRUS IGY AND COMPOSITE ANTIBODY

NºPublicación: WO2022165918A1 11/08/2022

Solicitante:

SHENZHEN JASON INTELLIGENT BIOENGINEERING LTD [CN]

Resumen de: WO2022165918A1

Provided in the present invention are a universal anti-coronavirus conservative epitope IgY and a broad-spectrum anti-mutation novel coronavirus IgY, and a composite antibody and a combined preparation. Provided in the present invention is a method for preparing the universal anti-coronavirus conservative epitope IgY and the broad-spectrum anti-variation novel coronavirus IgY antibody and an anti-mutation novel coronavirus IgY antibody and the combined antibody. Furthermore, the IgY and the composite IgY and the combined antibody can bind to a coronavirus universal conservative epitope and an antigen epitope with strong conservation, to achieve a broad-spectrum neutralizing virus effect, and the problems of coronavirus and novel coronavirus being prone to variation and immune escape and treating an asymptomatic patient are solved. Further provided in the present invention are a central air conditioner atomizing disinfectant and outer packaging disinfectant and an aerosol inhalation, spray, oral spray, nasal spray, nasal drops, eye drops, air disinfectant, hand sanitizer, powder, tablet, mouth lozenge, oral liquid and capsule made from the IgY and the composite IgY, which are used in drugs, disinfection products, health-care products and medical devices for preventing and treating coronavirus and novel coronavirus infections.

traducir

BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19

NºPublicación: WO2022170090A1 11/08/2022

Solicitante:

OMEROS CORP [US]

Resumen de: WO2022170090A1

Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2/C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2. Also disclosed are methods of using said compositions, methods and kits for detection of MASP-2/C1-INH complex to determine the status of lectin pathway activation in a mammalian subject and thereby assess the risk of a subject that is or has been infected with SARS-CoV-2 for developing COVID-19-related ARDS or other poor outcome, or determine the need for treatment or efficacy of treatment of a subject in need thereof with a complement inhibitor such as a MASP-2 inhibitory agent.

traducir

COLD-CHAIN FOOD PRODUCT OUTER PACKAGE DISINFECTING AND STERILIZING SYSTEM FOR NOVEL CORONAVIRUS

NºPublicación: WO2022166417A1 11/08/2022

Solicitante:

JIN LONG [CN]

CN_112826966_A

Resumen de: WO2022166417A1

Disclosed is a cold-chain food product outer package disinfecting and sterilizing system for a novel coronavirus. The system comprises a first-stage disinfecting and sterilizing chamber, a second-stage disinfecting and sterilizing chamber and a third-stage disinfecting and sterilizing chamber, which are sequentially in communication, and a central control chamber and a cloud data platform, which are connected to the disinfecting and sterilizing chambers of all the stages, wherein a conveying apparatus is arranged in the first-stage disinfecting and sterilizing chamber, the second-stage disinfecting and sterilizing chamber and the third-stage disinfecting and sterilizing chamber in a penetrating manner; a carrying robot arm and a labeling robot arm, which correspond to the conveying apparatus, are arranged at an inlet of the first-stage disinfecting and sterilizing chamber, and are used for carrying cold-chain articles onto the conveying apparatus and pasting two-dimensional code labels on the cold-chain articles on the conveying apparatus; multiple sets of ozone generators are arranged in the first-stage disinfecting and sterilizing chamber; multiple sets of ultraviolet sterilization lamps are arranged in the second-stage disinfecting and sterilizing chamber; and multiple sets of negative oxygen ion generators are arranged in the third-stage disinfecting and sterilizing chamber. In the system, novel coronaviruses on food packages can be effectively killed by means of the sequ

traducir

COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF

NºPublicación: WO2022170126A2 11/08/2022

Solicitante:

ADAGIO THERAPEUTICS INC [US]

Resumen de: WO2022170126A2

The present disclosure is directed to antibodies and antigen binding fragments thereof having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

traducir

MACHINE LEARNING FOR EARLY DETECTION OF CELLULAR MORPHOLOGICAL CHANGES

NºPublicación: WO2022170145A1 11/08/2022

Solicitante:

VIQI INC [US]

Resumen de: WO2022170145A1

Methods and systems for machine learning are disclosed for early detection of morphological changes in cell condition of biological cells. In one disclosed embodiment, the development of vaccines and anti-virals are sped up using machine learning to identify viral plaques earlier than can be detected using human observation alone. In the disclosed embodiment, detecting morphological changes in virus-infected cells can be made before plaques caused by cell death are observable (typical cell death in 2-14 days). Machine learning brings high-content/high-throughput techniques to the study of virology for the development of novel anti-viral compounds. Machine learning can also be used to characterize the effectiveness of novel anti-viral compounds on rapidly mutating viral strains, such as influenza and SARS-CoV-2.

traducir

TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS

NºPublicación: WO2022170155A2 11/08/2022

Solicitante:

BIOHAVEN THERAPEUTICS LTD [US]

Resumen de: WO2022170155A2

Among other things, the present disclosure provides agents that can bind to viruses such as SARS-CoV-2 and/or cells infected thereby. In some embodiments, the present disclosure provides methods for preventing and/or treating conditions, disorders or diseases associated with SARS-CoV-2 infection. In some embodiments, the present disclosure provides methods for preventing and/or treating COVID-19.

traducir

MULTIPLEXED, CRISPR-BASED DIAGNOSTICS OF SARS-COV-2 IN AUTONOMOUS MICROFLUIDIC DEVICE

NºPublicación: WO2022170013A1 11/08/2022

Solicitante:

UNIV CONNECTICUT [US]

Resumen de: WO2022170013A1

Described herein is an autonomous, rapid, sensitive, point-of-care target nucleic acid detection system and method based on CRISPR/Cas system. The system and method allow naked eye visualization of multiple target nucleic acid molecules simultaneously in a biological sample in less than an hour. Use of the system and method for multiplex gene diagnosis of SARS-CoV-2 is exemplified.

traducir

METHODS AND TREATMENT OF VIRAL INFECTION CAUSED BY SARS-COV-2

NºPublicación: WO2022169882A1 11/08/2022

Solicitante:

VERGE ANALYTICS INC [US]

Resumen de: WO2022169882A1

The present disclosure provides compounds that are useful for blocking SARS-CoV-2 from entering a host cell and preventing diseases and disorders caused by SARS-CoV-2, including COVID-19.

traducir

ADJUVANTED MUCOSAL SUBUNIT VACCINES FOR PREVENTING SARS-COV-2 TRANSMISSION AND INFECTION

NºPublicación: WO2022170119A1 11/08/2022

Solicitante:

US HEALTH [US]

Resumen de: WO2022170119A1

Immunogenic compositions that include SARS-CoV-2 spike (S) protein, S1 protein, or S2 protein, and an adjuvant, such as alum, or a combination of CpG oligodeoxynucleotide, Poly I:C, and IL-15, and nanoparticle compositions that include SARS-CoV-2 S protein, S1 protein, or S2 protein, and CpG oligonucleotide, poly(I:C), and IL-15, are provided. Also provided are methods of using such compositions, for example a prime intramuscular administration followed by one or more intranasal boosters that include the disclosed nanoparticles, to generate an immune response to SARS-CoV-2 in a subject, for example respiratory mucosal immunity, for example to prevent SARS-CoV-2 infection or transmission to other subjects.

traducir

ANTIBODIES

NºPublicación: WO2022167815A1 11/08/2022

Solicitante:

RQ BIOTECHNOLOGY LTD [GB]

WO_2022167816_A2

Resumen de: WO2022167815A1

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

traducir

MONITORING COVID-19 PROGRESSION AND TREATMENT

NºPublicación: WO2022167784A1 11/08/2022

Solicitante:

SEROXO LTD [GB]

Resumen de: WO2022167784A1

The present invention provides a rapid method using whole blood samples for determining the severity of COVID-19 disease arising from SARS-CoV-2 infection and monitoring progression and treatment of the disease relying on determination of the functionality of leukocytes (predominately neutrophils) to exhibit challenge-induced superoxide anion production with quantification by chemiluminescent measurement.

traducir

ANTIBODIES

NºPublicación: WO2022167816A2 11/08/2022

Solicitante:

UNIV OXFORD INNOVATION LTD [GB]

WO_2022167815_A1

Resumen de: WO2022167816A2

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

traducir

MUTATED RECOMBINANT ACE2-FC FUSION PROTEINS FOR THE TREATMENT OF COVID-19 INFECTIONS

NºPublicación: WO2022167947A1 11/08/2022

Solicitante:

RICHTER GEDEON NYRT [HU]
IMMUNOGENES KFT [HU]
PECSI TUDOMANYEGYETEM [HU]
EOETVOES LORAND TUDOMANYEGYETEM [HU]

Resumen de: WO2022167947A1

The invention relates to a mutated recombinant fusion protein comprising a human ACE2 domain and a human IgG-Fc domain, wherein in comparison to the ACE2 domain of SEQ ID NO: 1, the ACE2 domain of the mutated recombinant fusion protein comprises mutation (i) at positions R275, T373, H507; or (ii) at positions R275, H347, T373, H507, I515; or (iii) at positions R275, H347, H507, I515; or (iv) at position I515; or (v) at positions T373, I515; or (vi) at position H507; or (vii) at positions H507, I515; or (viii) at position T373. The invention also relates to said mutated recombinant fusion protein, further comprising a signal peptide. The invention further relates to said mutated recombinant fusion protein for use in a method of treating an infection disease caused by a coronavirus capable of binding ACE2. The invention also relates to a polynucleotide encoding said mutated recombinant fusion protein, and to a vector comprising said polynucleotide, as well as to a host cell comprising said vector.

traducir

USE OF DIAZEPAM AS ONLY TOLERATED BENZODIAZEPINE RECEPTOR AGONIST IN COVID-19 PATIENTS

NºPublicación: WO2022167685A1 11/08/2022

Solicitante:

HOPITAUX PARIS ASSIST PUBLIQUE [FR]
UNIV PARIS [FR]

EP_4039258_A1

Resumen de: WO2022167685A1

The present invention is based on the finding that Benzodiazepine Receptor Agonists (BZRA), including benzodiazepines and Z-drugs, are significantly associated with increased mortality among patients hospitalized for COVID-19, with a significant dose-dependent relationship. It is therefore suggested to decrease the dose or to taper off these medications, when possible, in these patients. Importantly, this lethal association was not observed for only one BZRA, namely diazepam. This knowledge will help guide clinicians on the choice of the molecule to prescribe to patients with COVID-19 with clinical indication of a BZRA treatment (e.g. patients with benzodiazepine use disorder, delirium tremens, epilepsy, alcohol withdrawal symptoms, etc…).

traducir

SARBECOVIRUS BINDERS

NºPublicación: WO2022167666A1 11/08/2022

Solicitante:

VIB VZW [BE]
UNIV GENT [BE]
UNIV BRUSSEL VRIJE [BE]

Resumen de: WO2022167666A1

The invention relates to agents binding to sarbecoviruses of multiple clades and potently neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Application and uses of these agents are further part of this invention.

traducir

TREATMENT AND METHOD OF IDENTIFYING CORONAVIRUS THERAPEUTICS

NºPublicación: WO2022167571A1 11/08/2022

Solicitante:

IMBA INST MOLEKULARE BIOTECH [AT]

Resumen de: WO2022167571A1

The invention provides a polypeptide or nucleic acid for use in a method of treating a coronavirus infection comprising administering a polypeptide comprising a carbohydrate recognition domain of CLEC4G or a nucleic acid encoding said polypeptide to a patient suffering from an infection with a coronavirus expressing a SARS-CoV-2 Spike protein.

traducir

METHOD FOR PROGNOSING THE COURSE OF A SARS-COV-2 INFECTION AND THE RESPONSE TO A SARS-COV-2 IMMUNIZATION AND/OR NATURAL INFECTION BY MEASURING SOLUBLE ACE2

NºPublicación: WO2022167526A1 11/08/2022

Solicitante:

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT [DE]
UNIV BERLIN CHARITE [DE]

EP_4039818_PA

Resumen de: WO2022167526A1

The present invention relates to an in-vitro-method for prognosing the course of a SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection and/or the response to a SARS-CoV-2 immunization and/or SARS-CoV-2 natural infection of a subject by using a-sACE2 and/or sACE2 as a marker. The invention further discloses an in-vitro-assay (A) for determining the amount of a-sACE2 and to an in-vitro-assay (B) for determining the amount of sACE2 in a sample. Additionally, a kit of parts for performing the in-vitro-assay (A), a kit of parts for performing the in-vitro-assay (B) and a kit of parts (C) for performing the in-vitro- method of the present invention are disclosed. Moreover, the present invention relates to a-sACE2 and/or sACE2 as a marker for prognosing the course of a SARS-CoV-2-infection and/or the response to a SARS-CoV-2 immunization and/or SARS-CoV-2 natural infection.

traducir

SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS

NºPublicación: WO2022167831A1 11/08/2022

Solicitante:

PASTEUR INSTITUT [FR]
THERAVECTYS [FR]

Resumen de: WO2022167831A1

A method of inducing a protective immune response against Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2), comprising administering to the upper respiratory tract of a subject an effective amount of an agent that induces a protective immune response against SARS-CoV-2. A dosage form for administration to the upper respiratory tract of a pseudotyped lentiviral vector particle encoding a Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2) spike (S) protein or a derivative or fragment thereof.

traducir

SIGMA RECEPTOR LIGANDS FOR TREATING SARS-COV-2 INFECTION

NºPublicación: WO2022169961A1 11/08/2022

Solicitante:

UNIV FLORIDA [US]

Resumen de: WO2022169961A1

The invention relates to compounds, compositions, and methods of treating viral infection, especially SARS-CoV-2 infection.

traducir

METHOD OF PREVENTING COVID-19 INFECTION

NºPublicación: US2022249547A1 11/08/2022

Solicitante:

HAZAN SABINE [US]

US_2021299091_A1

Resumen de: US2022249547A1

A product for preventing COVID-19 infection in an individual, the product comprising a combination of vitamin C, vitamin D, and zinc. The combination comprises 1,000 mg to 10,000 mg of vitamin C, 3,000 IU to 40,000 IU of vitamin D, and 25 mg to 75 mg of zinc. The combination is administered daily for two or more days for prophylaxis, or the combination is administered weekly over a period of two or more weeks for prophylaxis.

traducir

Treatment of Acute Medical Conditions

Nº publicación: US2022249840A1 11/08/2022

Solicitante:

GALVANI BIOELECTRONICS LTD [GB]

WO_2020254793_A1

Resumen de: US2022249840A1

Electrical stimulation of neural activity in the neural innervation of the spleen that is associated with neurovascular bundles provides a useful way to treat acute medical conditions, such as trauma, hemorrhaging, shock, acute respiratory distress syndrome (ARDS), severe respiratory distress syndrome (SARS), and coronavirus disease 19 (COVID-19).

traducir

Página1 de 18 nextPage por página

punteroimgVolver